title: Continuous ambulatory peritoneal dialysis in end-stage renal disease due to multiple myeloma.
abstract: OBJECTIVE
  To evaluate (1) the disease course, (2) the response to recombinant human erythropoietin (rHuEPO), and (3) the morbidity and mortality of patients with end-stage renal disease (ESRD) due to multiple myeloma (MM) who were treated with continuous ambulatory peritoneal dialysis (CAPD) DESIGN: Retrospective study.
  
  
  METHODS
  Tertiary teaching hospital--The Toronto Hospital, Toronto, Ontario, Canada.
  
  
  METHODS
  Seven patients with ESRD due to MM who were treated with CAPD.
  
  
  RESULTS
  Mean age of the patients was 77.2 years (median 80 years, range 65-88 years). Two were in stage IB, 1 was in stage IIB, and the remaining 4 were in stage IIIB, according to Durie and Salmon's staging. Three patients received rHuEPO; 2 of these also were receiving chemotherapy for myeloma. The mean rHuEPO requirement was 277 U/kg/wk, which was more than other ESRD patients' requirements. Mean duration of CAPD was 20.6 months (6-58 months). The peritonitis rate was one episode in 14.4 months. The frequency of hospitalization was once in 5.6 months, and the mean number of days spent in hospital was 20 days per year. Quality of life did not get worse and, if anything, improved marginally while they were on CAPD. Three patients died after a mean survival of 32.7 months, and the remaining 4 patients are still alive.
  
  
  CONCLUSIONS
  Myeloma patients with ESRD do fairly well on CAPD without deterioration in their quality of life and with an acceptable peritonitis rate.
authors.affiliation: Toronto Western Hospital, Ontario, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Shetty
authors.forename: D G
authors.initials: DG
authors.lastname: Oreopoulos
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018450:Disease Progression; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006760:Hospitalization; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D007710:Klebsiella Infections; D007902:Length of Stay; D008297:Male; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D010538:Peritonitis / Q000209:etiology / Q000382:microbiology; D011788:Quality of Life; D011994:Recombinant Proteins; D012189:Retrospective Studies; D013290:Streptococcal Infections; D015996:Survival Rate; D013997:Time Factors
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin